Accolade (NASDAQ:ACCD) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Accolade (NASDAQ:ACCD) released its earnings results on Thursday. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01, Briefing.com reports. The business had revenue of $124.80 million during the quarter, compared to analysts’ expectations of $123.91 million. Accolade had a negative net margin of 31.59% and a negative return on equity of 27.27%. The company’s quarterly revenue was up 26.1% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.42) earnings per share. Accolade updated its FY 2025 guidance to EPS and its Q1 2025 guidance to EPS.

Accolade Trading Down 15.6 %

Accolade stock traded down $1.43 during trading on Friday, hitting $7.76. The company had a trading volume of 955,055 shares, compared to its average volume of 721,127. The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 0.48. The company’s 50 day simple moving average is $9.75 and its 200-day simple moving average is $9.92. Accolade has a 1-year low of $6.33 and a 1-year high of $17.00. The stock has a market cap of $600.70 million, a price-to-earnings ratio of -4.81 and a beta of 2.08.

Wall Street Analyst Weigh In

A number of equities analysts have commented on ACCD shares. William Blair reissued an “outperform” rating on shares of Accolade in a report on Tuesday, January 9th. Canaccord Genuity Group reduced their price objective on Accolade from $18.00 to $16.00 and set a “buy” rating for the company in a research note on Friday. Wells Fargo & Company lifted their target price on shares of Accolade from $10.00 to $12.00 and gave the stock an “equal weight” rating in a research note on Tuesday, January 9th. Needham & Company LLC reduced their target price on shares of Accolade from $17.00 to $13.00 and set a “buy” rating for the company in a research report on Friday. Finally, Truist Financial lowered their price target on shares of Accolade from $16.00 to $14.00 and set a “buy” rating on the stock in a research report on Friday. Four investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $14.80.

Accolade Company Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians.